title: [Pleural metastases from bronchial carcinoma: is a cure possible?].
abstract: BACKGROUND
  The 2009 TNM classification of lung cancer reclassified patients with pleural invasion from stage IIIB (T4) to stage IV (M+). However, the 2009 TNM separates patients with pleural metastases (M1a) from patients with others visceral metastases (M1b), the patients with stage M1a having the better prognosis.
  
  
  METHODS
  Two cases are reported of patients with non-small cell lung cancer (NSCLC) metastatic to the pleura, having a long disease free survival (50 and 34 months).
  
  
  CONCLUSIONS
  Patients with pleural metastases from NSCLC seem to have a better prognosis than other patients with stage IV disease, maybe because of a subgroup of patients with long survival. This long survival is probably related to specific biological characteristics of certain pleural disorders that need to be identified. This would allow a more aggressive treatment of this subgroup of patients regarded today as incurable.
authors.affiliation: Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Pôle Cardiovasculaire et Thoracique, Hôpital Nord, Assistance publique-Hôpitaux de Marseille, Université de la Méditerranée, Chemin des Bourrely, 13915 Marseille cedex 20, France.
authors.forename: P
authors.initials: P
authors.lastname: Tomasini
authors.forename: F
authors.initials: F
authors.lastname: Barlesi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010880:Piperidines / Q000008:administration & dosage; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D011799:Quinazolines / Q000008:administration & dosage; D011878:Radiotherapy; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D019233:Retreatment; D017741:Survivors; D013908:Thoracotomy
chemical_list: D010880:Piperidines; D011799:Quinazolines; D020794:Receptor Protein-Tyrosine Kinases; C452423:vandetanib